Latest News

FDA expands pembrolizumab approval for advanced melanoma


 

The Food and Drug Administration has approved pembrolizumab (Keytruda) for the adjuvant treatment of stage IIB and IIC melanoma after complete resection in adults and children over age 12 years. The FDA also extended the approval to those with stage III disease.

The FDA approval on Dec. 3 was based on first interim findings from the randomized, placebo-controlled KEYNOTE-716 trial, which evaluated patients with stage IIB and IIC disease.

Since the anti-PD-1 therapy was approved in metastatic melanoma 7 years ago, “we have built on this foundation in melanoma and have expanded the use of KEYTRUDA into earlier stages of this disease,” said Scot Ebbinghaus, MD, vice president, clinical research, Merck Research Laboratories, in a press release. “With today’s approval, we can now offer health care providers and patients 12 years and older the opportunity to help prevent melanoma recurrence with Keytruda across resected stage IIB, stage IIC, and stage III melanoma.”

In KEYNOTE-716, patients with completely resected stage IIB or IIC melanoma were randomly assigned to receive 200 mg of intravenous pembrolizumab, the pediatric dose 2 mg/kg (up to a maximum of 200 mg) every 3 weeks, or placebo for up to 1 year until disease recurrence or unacceptable toxicity.

After a median follow-up of 14.4 months, investigators reported a statistically significant 35% improvement in recurrence-free survival (RFS) in those treated with pembrolizumab, compared with those who received placebo (hazard ratio, 0.65).

The most common adverse reactions reported in patients receiving pembrolizumab in KEYNOTE-716 were fatigue, diarrhea, pruritus, and arthralgia, each occurring in at least 20% of patients.

“Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of Keytruda,” according to Merck.

A version of this article first appeared on Medscape.com.

Recommended Reading

New cancer drugs may have saved more than 1.2 million Americans
Journal of Clinical Outcomes Management
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Journal of Clinical Outcomes Management
Cancer rates on the rise in adolescents and young adults
Journal of Clinical Outcomes Management
COVID-19 vaccination in cancer patients: NCCN outlines priorities
Journal of Clinical Outcomes Management
Don’t delay: Cancer patients need both doses of COVID vaccine
Journal of Clinical Outcomes Management
Possible obesity effect detected in cancer death rates
Journal of Clinical Outcomes Management
Americans’ sun protection practices fall short of intentions
Journal of Clinical Outcomes Management
Stop using Neutrogena and Aveeno spray sunscreen, J&J warns
Journal of Clinical Outcomes Management
Differences in response to immunotherapy in men versus women
Journal of Clinical Outcomes Management
‘Highest survival’ with combo immunotherapy in advanced melanoma
Journal of Clinical Outcomes Management